CAS 1440964-89-5

Fórmula: C20H15F3N8

InChI: InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3

Chave InChI: QHXLXUIZUCJRKV-UHFFFAOYSA-N

SMILES: CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F

Bozitinib

CAS: 1440964-89-5

Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.

Fórmula: C₂₀H₁₅F₃N₈

Pureza: 99.16%

Cor e Forma: Solid

Peso molecular: 424.3819

Ref: TM-T10585

Bozitinib

CAS: 1440964-89-5

Bozitinib

Fórmula: C₂₀H₁₅F₃N₈

Pureza: ≥98%

Peso molecular: 424.38

Ref: 54-BUP02411

6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine

CAS: 1440964-89-5

Fórmula: C₂₀H₁₅F₃N₈

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 424.3819

Ref: IN-DA01WTC0

Bozitinib (PLB-1001)

CAS: 1440964-89-5

Fórmula: C₂₀H₁₅F₃N₈

Peso molecular: 424.39

Ref: 4Z-B-268001

Bozitinib

CAS: 1440964-89-5

Fórmula: C₂₀H₁₅F₃N₈

Peso molecular: 424.4

Ref: BE-RMCB181001

Bozitinib

CAS: 1440964-89-5

6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine

Fórmula: C₂₀H₁₅F₃N₈

Pureza: 98%

Peso molecular: 424.38

Ref: IN-DG00978663

Bozitinib (PLB-1001)

CAS: 1440964-89-5

Bosutinib is a CDK4/6 inhibitor that inhibits the activity of proteins that regulate cell division. Bosutinib has been shown to have anti-cancer properties by inhibiting the growth of cancer cells in preclinical models. Bosutinib also inhibits epidermal growth factor (EGF) and tumor necrosis factor (TNF). Bosutinib has been shown to have clinical benefit in patients with subcutaneous tumors, glioma, and other cancers. Bosutinib has not been evaluated in pregnant women or children and should be used only if potential benefits outweigh risks.

Fórmula: C₂₀H₁₅F₃N₈

Pureza: Min. 95%

Peso molecular: 424.38 g/mol

Ref: 3D-QHC96489